

**A randomised, double-blind study comparing the gastrointestinal tolerability of tegomil fumarate
versus dimethyl fumarate in healthy volunteers**


Authors: Marlene Fonseca¹, Gabriel Bauzà Valverde², Abdelkarim Bendarráz², Carmen Catalán
Flores², Vikas Mohan Sharma²

Affiliations: ¹BlueClinical Phase I, Hospital da Prelada, Porto, Portugal; ²Scientific Department,
Neuraxpharm, Barcelona, Spain

Corresponding author: Marlene Fonseca, Email: marlene.fonseca@astrumcro.com

Supplementary materials

Supplementary Figure S1. Between-group difference in the area under the curve for the Modified Overall Gastrointestinal Symptom Scale total and composite scores over the 5-week treatment phase in male and female participants. *AUC* area under the curve, *CI* confidence interval, *DMF* dimethyl fumarate, *LSM* least squares mean, *MOGISS* Modified Overall Gastrointestinal Symptom Scale, *TMF* tegomil fumarate



Supplementary Figure S2. Mean number of symptoms with any Modified Overall Gastrointestinal

Symptom Scale intensity score ≥ 1 over time. *DMF* dimethyl fumarate, *TMF* tegomil fumarate

